Search hospitals > Louisiana > New Orleans
University Medical Center New Orleans
Claim this profileNew Orleans, Louisiana 70112
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Coronavirus
255 reported clinical trials
29 medical researchers
Summary
University Medical Center New Orleans is a medical facility located in New Orleans, Louisiana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Coronavirus and other specialties. University Medical Center New Orleans is involved with conducting 255 clinical trials across 442 conditions. There are 29 research doctors associated with this hospital, such as Scott E. Delacroix, Brian C. Boulmay, Augusto C. Ochoa, and Agustin Garcia, M.D..Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Scott E. DelacroixLSU Healthcare Network / Metairie Multi-Specialty Clinic2 years of reported clinical research
Expert in Prostate Cancer
Expert in Cancer
26 reported clinical trials
61 drugs studied
Brian C. BoulmayUniversity Medical Center New Orleans4 years of reported clinical research
Studies Cancer
Studies Lung Cancer
17 reported clinical trials
27 drugs studied
Augusto C. OchoaGulfport Memorial Hospital7 years of reported clinical research
Studies Breast Cancer
Studies Cancer
15 reported clinical trials
69 drugs studied
Agustin Garcia, M.D.University Medical Center New Orleans8 years of reported clinical research
Studies Breast Cancer
Studies Tumors
9 reported clinical trials
18 drugs studied
Clinical Trials running at University Medical Center New Orleans
Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Squamous Cell Carcinoma
Renal Cell Carcinoma
Bladder Cancer
Ovarian Cancer
Oropharyngeal Carcinoma
Tumors
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
Sacituzumab Govitecan + Pembrolizumab
for Triple Negative Breast Cancer
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Recruiting2 awards Phase 36 criteria
ARV-471
for Breast Cancer
This trial tests a new oral medicine, ARV-471, against an existing injectable treatment, fulvestrant, in people with advanced breast cancer that has spread. Both medicines aim to slow cancer growth by targeting estrogen receptors. ARV-471 is developed as an oral alternative to fulvestrant.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University Medical Center New Orleans?
University Medical Center New Orleans is a medical facility located in New Orleans, Louisiana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Coronavirus and other specialties. University Medical Center New Orleans is involved with conducting 255 clinical trials across 442 conditions. There are 29 research doctors associated with this hospital, such as Scott E. Delacroix, Brian C. Boulmay, Augusto C. Ochoa, and Agustin Garcia, M.D..